BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar

Patrick Tang, MD PhD^{1#}, Mohammad R. Hasan, PhD^{1#}, Hiam Chemaitelly, MSc^{2,3#}, Hadi M. Yassine, PhD^{4,5}, Fatiha M. Benslimane, PhD^{4,5}, Hebah A. Al Khatib, PhD^{4,5}, Sawsan AlMukdad, MSc^{2,3}, Peter Coyle, MD^{4,6,7}, Houssein H. Ayoub, PhD⁸, Zaina Al Kanaani, PhD⁶, Einas Al Kuwari, MD⁶, Andrew Jeremijenko, MD⁶, Anvar Hassan Kaleeckal, MSc⁶, Ali Nizar Latif, MD⁶, Riyazuddin Mohammad Shaik, MSc⁶, Hanan F. Abdul Rahim, PhD⁹, Gheyath K. Nasrallah, PhD^{4,5}, Mohamed Ghaith Al Kuwari, MD¹⁰, Hamad Eid Al Romaihi, MD¹¹, Adeel A. Butt, MBBS MS^{6,12}, Mohamed H. Al-Thani, MD¹¹, Abdullatif Al Khal, MD⁶, Roberto Bertollini, MD MPH¹¹, and Laith J. Abu-Raddad, PhD^{2,3,9,12*}

#Authors are joint first authors in this study.

¹Department of Pathology, Sidra Medicine, Doha, Qatar

²Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar

³World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar

⁴Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar

⁵Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar

⁶Hamad Medical Corporation, Doha, Qatar

⁷Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom

⁸Department of Mathematics, Statistics, and Physics, Qatar University, Doha, Qatar

⁹Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar

¹⁰Primary Health Care Corporation, Doha, Qatar

¹¹Ministry of Public Health, Doha, Qatar

¹²Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA

Word count: Abstract: 165 words, Main Text: 2,178 words.

Number of figures: 1.

Number of tables: 1.

Running title: Effectiveness of BNT162b2 and mRNA-1273 against Delta

Keywords: SARS-CoV-2, epidemiology, vaccine, variant, infection, dose, case-control.

*correspondence to Professor Laith J. Abu-Raddad, E-mail: lja2002@qatar-med.cornell.edu.

Abstract

The SARS-CoV-2 Delta (B.1.617.2) variant of concern is expanding globally. Here, we assess real-world effectiveness of the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines against this variant in the population of Qatar, using a matched test-negative, case-control study design. BNT162b2 effectiveness against any Delta infection, symptomatic or asymptomatic, was 64.2% (95% CI: 38.1-80.1%) ≥ 14 days after the first dose and before the second dose, but was only 53.5% (95% CI: 43.9-61.4%) ≥ 14 days after the second dose, in a population in which a large proportion of fully vaccinated persons received their second dose several months earlier. Corresponding effectiveness measures for mRNA-1273 were 79.0% (95% CI: 58.9-90.1%) and 84.8% (95% CI: 75.9-90.8%), respectively. Effectiveness against any severe, critical, or fatal COVID-19 disease due to Delta was 89.7% (95% CI: 61.0-98.1%) for BNT162b2 and 100.0% (95% CI: 41.2-100.0%) for mRNA-1273, ≥ 14 days after the second dose. Both BNT162b2 and mRNA-1273 are highly effective in preventing Delta hospitalization and death, but less so in preventing infection, particularly for BNT162b2.

Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta (B.1.617.2) variant of concern is expanding globally¹. Appreciable community transmission of this variant was first detected in Qatar toward the end of March, 2021²⁻⁴. While the incidence of Delta has been increasing, it remained relatively low. Though there has been a recent surge in cases, no evidence for a clear epidemic wave has materialized as of August 10, 2021. In contrast, the introduction of both the Alpha (B.1.1.7) and Beta (B.1.351) variants led to two rapid back-to-back SARS-CoV-2 waves earlier in 2021²⁻⁶. The high Coronavirus Disease 2019 (COVID-19) vaccine coverage in Qatar at the present time may have slowed Delta transmission. As of August 10, 2021, 87.8% of persons ≥ 12 years of age have received at least one vaccine dose of either the BNT162b2⁷ (Pfizer-BioNTech) vaccine or the mRNA-1273⁸ (Moderna) vaccine, and 73.8% have received both doses⁹. In the present study, we assessed real-world effectiveness of the BNT162b2 and mRNA-1273 vaccines against the Delta variant.

Results

Study population

Between December 21, 2020 and July 21, 2021, 906,078 individuals in Qatar received at least one dose of BNT162b2, and 877,354 completed the two-dose regimen. The median date at first dose was April 18, 2021, and the median date at second dose was May 7, 2021. The median time elapsed between the first and second doses was 21 days (interquartile range (IQR): 21-22 days), and 97.7% of individuals received their second dose ≤ 30 days after the first dose.

During the same time interval, 490,828 individuals received at least one dose of mRNA-1273, and 409,041 completed the two-dose regimen. The median date at first dose was April 18, 2021,

and the median date at second dose was May 12, 2021. Median time elapsed between the first and second doses was 28 days (IQR: 28-31 days), and 74.6% of individuals received their second dose ≤ 30 days after the first dose.

As a consequence of the schedule of arriving vaccine shipments, BNT162b2 vaccine coverage increased incrementally and steadily from December 2020 and up to the present. Meanwhile, the increases in mRNA-1273 vaccine coverage occurred in specific times following arrival of large shipments, and was not appreciable before March of 2021.

Supplementary Data 1-3 provide flowcharts describing the population selection process for investigating and estimating vaccine effectiveness against Delta for the BNT162b2 vaccine (Supplementary Data 1), the mRNA-1273 vaccine (Supplementary Data 2), and any vaccination with either BNT162b2 or mRNA-1273 (Supplementary Data 3). Demographic characteristics of samples used to estimate vaccine effectiveness ≥ 14 days after the first dose and ≥ 14 days after the second dose are presented in Tables 1 and 2, respectively. Median age in the study samples was 31-32 years. Qatar has unusually young, diverse demographics, in that only 9% of its residents are ≥ 50 years of age, and 89% are expatriates from over 150 countries^{10,11}.

Delta vaccine-breakthrough infections

As of the end of the study, July 21, 2021, 54 and 249 Delta breakthrough infections had been recorded among those who received either one or two doses of BNT162b2, respectively, and 27 and 26 breakthrough infections had been recorded among those who received mRNA-1273, respectively.

Also, as of July 21, 2021, 3 and 4 severe Delta COVID-19 disease cases (acute-care hospitalizations¹²; Methods) had been recorded among those who received either one or two

doses of BNT162b2, respectively, and 3 severe disease cases had been recorded among those who received only one dose of mRNA-1273. No severe Delta disease cases were recorded among those who received two doses of mRNA-1273.

Meanwhile, 1 critical Delta COVID-19 disease case (ICU-care hospitalization¹²; Methods) had been recorded among those who received two doses of BNT162b2. No critical disease cases were recorded among those who received only one dose of BNT162b2, or among those who received one or two doses of mRNA-1273. No fatal Delta COVID-19 disease cases (COVID-19 deaths¹³; Methods) were recorded among those who received either vaccine.

Vaccine effectiveness ≥ 14 days after the first dose

Estimated BNT162b2 effectiveness against infection with Delta, defined as a polymerase chain reaction (PCR)-positive swab with the Delta variant, regardless of the reason for PCR testing or presence of symptoms (Methods), was 64.2% (95% confidence interval (CI): 38.1-80.1%) 14 or more days after the first dose, but before receiving the second dose (Table 3). The corresponding effectiveness for mRNA-1273 was 79.0% (95% CI: 58.9-90.1%), and for vaccination with either BNT162b2 or mRNA-1273, it was 68.9% (95% CI: 52.7-80.1%).

Estimated vaccine effectiveness against any severe¹², critical¹², or fatal¹³ COVID-19 disease due to any Delta infection (Methods), 14 or more days after the first dose, but before receiving the second dose, was 100% for BNT162b2, mRNA-1273, and either BNT162b2 or mRNA-1273, but with very wide 95% confidence intervals due to the relatively small number of severe, critical, and fatal disease cases in this analysis (Table 3).

Vaccine effectiveness ≥ 14 days after the second dose

Estimated BNT162b2 effectiveness against infection with Delta was 53.5% (95% CI: 43.9-61.4%) 14 or more days after the second dose (Table 3). The corresponding effectiveness for mRNA-1273 was 84.8% (95% CI: 75.9-90.8%), and for vaccination with either BNT162b2 or mRNA-1273, it was 57.2% (95% CI: 48.9-64.1%).

Estimated BNT162b2 effectiveness against any severe¹², critical¹², or fatal¹³ COVID-19 disease due to any Delta infection was 89.7% (95% CI: 61.0-98.1%) 14 or more days after the second dose (Table 3). The corresponding effectiveness for mRNA-1273 was 100.0% (95% CI: 41.2-100.0%), and for vaccination with either BNT162b2 or mRNA-1273, it was 92.6% (95% CI: 72.7-98.6%).

Additional analyses

Sensitivity analyses adjusting for sex, age, nationality, reason for PCR testing, and calendar week of PCR test in logistic regression analysis confirmed main analysis results, but with slightly higher estimated effectiveness (Table 4).

An additional analysis estimated BNT162b2 effectiveness against symptomatic Delta infection at 56.1% (95% CI: 41.4-67.2%) 14 or more days after the second dose (Table 5). The corresponding effectiveness for mRNA-1273 was 85.8% (95% CI: 70.6-93.9%), and for vaccination with either BNT162b2 or mRNA-1273, it was 62.0% (95% CI: 50.0-71.1%).

Symptomatic infection was defined as a PCR-positive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.

An additional analysis estimated BNT162b2 effectiveness against asymptomatic Delta infection at 35.9% (95% CI: 11.1-53.9%) 14 or more days after the second dose (Table 5). The corresponding effectiveness for mRNA-1273 was 80.2% (95% CI: 54.2-92.6%), and for

vaccination with either BNT162b2 or mRNA-1273, it was 40.0% (95% CI: 18.2-56.1%).

Asymptomatic infection was defined as a PCR-positive test conducted with no reported presence of symptoms compatible with a respiratory tract infection, that is, strictly, the PCR testing was done as only part of a survey, for pre-travel requirement, or at port of entry upon arrival into the country^{10,14}.

Discussion

Both the BNT162b2 and mRNA-1273 vaccines demonstrated robust effectiveness ($\geq 90\%$) against hospitalization and death due to infection with the Delta variant, confirming recently announced estimates from the United Kingdom (UK)¹⁵ and Israel¹⁶. Although there were many breakthrough infections, especially for BNT162b2, severe or critical COVID-19 disease cases among vaccinated persons were rare. Among those fully vaccinated with BNT162b2, there were only 4 severe disease cases and 1 critical disease case due to Delta, while for mRNA-1273, there were only 3 severe disease cases and no critical disease cases. No COVID-19 deaths due to Delta were recorded in a person vaccinated with either vaccine.

BNT162b2 effectiveness against any infection with Delta, symptomatic or asymptomatic, 14 or more days after the first dose, was 64.2%, compared to 46.5%¹⁷ against Beta (B.1.351) and 65.5%¹⁷ against Alpha (B.1.1.7), in the same population of Qatar. This result is consistent with existing evidence suggesting that Beta is the most immune-evasive variant of the known variants of concern^{18,19}. However, BNT162b2 effectiveness against Delta 14 or more days after the second dose was only 53.5%, compared to 75.0%^{5,17} against Beta and 89.5%^{5,17} against Alpha. Strikingly, estimated BNT162b2 effectiveness against Delta 14 or more days after the first dose, or 14 or more days after the second dose, were statistically similar.

Emerging evidence suggests significant waning of BNT162b2 effectiveness over time²⁰⁻²².

Effectiveness against Beta was estimated at a time when nearly all persons in Qatar were newly vaccinated with BNT162b2^{5,17}, but effectiveness against Delta was estimated (in the present study) at a time when a large proportion of those BNT162b2 vaccinated had received their second dose several months earlier. The unexpectedly low effectiveness against Delta among fully vaccinated persons may thus reflect some waning of BNT162b2 protection over time.

This explanation is consistent with the pattern seen in emerging effectiveness estimates against Delta in other countries. Our estimate of 53.5% among fully vaccinated persons is lower than that found in the UK^{23,24} and Canada²⁵, where effectiveness was estimated at >75%, but higher than that in Israel at only 39%¹⁶ and the United States (USA) at 42%²⁶. With the delayed second dose in the UK and Canada, most BNT162b2-vaccinated persons received their second dose three months or so more recently than in Israel, USA, and Qatar, where the second dose was administered three weeks after the first dose. The lower effectiveness in Israel, USA, and Qatar may thus reflect waning of vaccine protection for those who received their second dose by end of 2020 or early 2021. Qatar started its mass vaccination campaign with BNT162b2 shortly after that of Israel and the USA.

Another factor may also help to explain this low effectiveness. Public health restrictions have gradually been easing in Qatar over the last few weeks, coinciding with the period during which Delta incidence has been slowly increasing. Restrictions, however, have been eased differently for vaccinated and unvaccinated persons. Many social, work, and travel activities at present require evidence of vaccination (a “health pass”) that is administered through a mandatory mobile app (the Ehteraz app). Vaccinated persons presumably have a higher social contact rate than unvaccinated persons, and may have also reduced their adherence to safety measures, such

as protective masks, with the perception of vaccine protection²⁷⁻²⁹. Such risk compensation may be even higher with increasing time since receiving the second dose, leading to progressive normalization of behavior²⁸⁻³⁰. Risk of exposure to the virus could thus be higher among vaccinated persons than among unvaccinated persons, thereby diminishing the observed real-world vaccine effectiveness relative to the actual biological vaccine effectiveness.

mRNA-1273 effectiveness against infection with Delta was higher than that of BNT162b2, consistent with evidence suggesting that mRNA-1273 induces stronger immune response and protection^{6,31-33}. mRNA-1273 effectiveness against Delta, 14 or more days after the first dose, was 79.0%, compared to 61.3%⁶ against Beta and 88.1%⁶ against Alpha, in the same population in Qatar. This result is also consistent with Beta's being the most immune-evasive variant^{18,19}. However, mRNA-1273 effectiveness against Delta, 14 or more days after the second dose, was only 84.8%, compared to 96.4%⁶ against Beta and 100%⁶ against Alpha. The same factors that may explain the low BNT162b2 effectiveness against Delta among fully vaccinated persons may also explain the less-than-expected mRNA-1273 effectiveness against Delta among fully vaccinated persons. However, there has been less time for waning of vaccine immunity for mRNA-1273, as this vaccine was incorporated into the national immunization campaign nearly three months after BNT162b2^{5,6,17}.

There was evidence for a gradient in vaccine effectiveness by appearance of symptoms, that is, greater protection against more symptomatic or severe infections, as observed earlier for BNT162b2 and mRNA-1273 effectiveness against the Alpha and Beta variants^{5,6,17,25}.

This study has limitations. Estimated effectiveness against severe, critical, or fatal COVID-19 disease had wider 95% confidence intervals than that against infection, as a consequence of the smaller number of such cases in the young population of Qatar^{10,34}. Data on co-morbid

conditions were not available; therefore, they could not be factored explicitly in our analysis.

However, adjusting for age may have served as a proxy given that co-morbidities are associated with older age. Furthermore, with the young population of Qatar^{10,11}, we anticipate that only a small proportion of the study population may have had serious co-morbid conditions.

Accordingly, our findings may not be generalizable to other settings where the elderly population constitutes a sizable proportion of the population. Effectiveness was assessed using an observational test-negative case-control study design^{35,36}, rather than a randomized clinical trial design where cohorts of vaccinated and unvaccinated individuals were being followed up.

However, the cohort study design applied to the same population of Qatar yielded earlier similar findings to the test-negative case-control study design^{5,6}, supporting the validity of this standard approach in assessing vaccine effectiveness for respiratory tract infections^{35,36}.

In conclusion, both the BNT162b2 and mRNA-1273 vaccines are highly effective in preventing hospitalization and death due to infection with the Delta variant. However, effectiveness against infection was considerably lower than that against serious COVID-19 disease, particularly for the BNT162b2 vaccine. The reasons for the inferior protection against infection remain to be determined, and may not necessarily relate to immune evasion by the Delta variant. The lower effectiveness may reflect some waning of BNT162b2 vaccine protection over time, or higher risk of exposure to the virus among vaccinated persons compared to unvaccinated persons, due to higher social contact rate and less adherence to safety measures.

Acknowledgements

We acknowledge the many dedicated individuals at Hamad Medical Corporation, the Ministry of Public Health, the Primary Health Care Corporation, Qatar Biobank, Sidra Medicine, and Weill Cornell Medicine for their diligent efforts and contributions to make this study possible. The authors are grateful for institutional salary support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as for institutional salary support provided by the Ministry of Public Health and Hamad Medical Corporation. The authors are also grateful for the Qatar Genome Programme for institutional support for the reagents needed for the viral genome sequencing. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. Statements made herein are solely the responsibility of the authors.

Author contributions

PT and MRH conducted the multiplex, RT-qPCR variant screening and viral genome sequencing. HC co-designed the study, performed the statistical analyses, and co-wrote the first draft of the article. LJA conceived and co-designed the study, led the statistical analyses, and co-wrote the first draft of the article. HY, FMB, and HAK conducted viral genome sequencing. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and to the writing of the manuscript. All authors have read and approved the final manuscript.

Competing interests

Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise, we declare no competing interests.

References

1. World Health Organization. Tracking SARS-CoV-2 variants. Available from: <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>. Accessed on: June 5, 2021. (2021).
2. National Project of Surveillance for Variants of Concern and Viral Genome Sequencing. Qatar viral genome sequencing data. Data on randomly collected samples. <https://www.gisaid.org/phylogenetics/global/nextstrain/>. (2021).
3. Benslimane, F.M., *et al.* One year of SARS-CoV-2: Genomic characterization of COVID-19 outbreak in Qatar. *medRxiv*, 2021.2005.2019.21257433 (2021).
4. Hasan, M.R., *et al.* Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar. *medRxiv*, 2021.2007.2018.21260718 (2021).
5. Abu-Raddad, L.J., Chemaitelly, H., Butt, A.A. & National Study Group for Covid-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *N Engl J Med* (2021).
6. Chemaitelly, H., *et al.* mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nat Med* (2021).
7. Polack, F.P., *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* (2020).
8. Baden, L.R., *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* **384**, 403-416 (2021).
9. Ministry of Public Health. National Covid-19 Vaccination Program Data. <https://covid19.moph.gov.qa/EN/Pages/Vaccination-Program-Data.aspx>. Access date August 2, 2021. (2021).
10. Abu-Raddad, L.J., *et al.* Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. *Scientific Reports* **11**, 6233 (2021).
11. Planning and Statistics Authority-State of Qatar. Qatar Monthly Statistics. Available from: <https://www.psa.gov.qa/en/pages/default.aspx>. Accessed on: May 26, 2020. (2020).
12. World Health Organization. COVID-19 clinical management: living guidance. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1>. Accessed on: May 15, 2021. (2021).
13. World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as cause of death. Available from: https://www.who.int/classifications/icd/Guidelines_Cause_of_Death_COVID-19-20200420-EN.pdf?ua=1. Document Number: WHO/HQ/DDI/DNA/CAT. Accessed on May 15, 2021. (2020).
14. Bertollini, R., *et al.* Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar. *JAMA* (2021).
15. Stowe, J., *et al.* Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZIEig/view_file/479607329?com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZIEig_redirect=https%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F%25. (2021).

16. Israel's Ministry of Health. COVID-19 vaccine effectiveness against the Delta variant. Israel's Ministry of Health report. https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf. (2021).
17. Abu-Raddad, L.J., *et al.* Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. *J Travel Med* (2021).
18. Wang, P., *et al.* Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature* (2021).
19. Planas, D., *et al.* Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. *Nat Med* (2021).
20. Israel, A., *et al.* Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort. *medRxiv*, 2021.2008.2003.21261496 (2021).
21. Thomas, S.J., *et al.* Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. *medRxiv*, 2021.2007.2028.21261159 (2021).
22. Mizrahi, B., *et al.* Correlation of SARS-CoV-2 Breakthrough Infections to Time-from-vaccine; Preliminary Study. *medRxiv*, 2021.2007.2029.21261317 (2021).
23. Lopez Bernal, J., *et al.* Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med* (2021).
24. Sheikh, A., McMenamin, J., Taylor, B. & Robertson, C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *The Lancet* **397**, 2461-2462 (2021).
25. Nasreen, S., *et al.* Effectiveness of COVID-19 vaccines against variants of concern, Canada. *medRxiv*, 2021.2006.2028.21259420 (2021).
26. Puranik, A., *et al.* Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. *medRxiv*, 2021.2008.2006.21261707 (2021).
27. Makhoul M., *et al.* Epidemiological impact of SARS-CoV-2 vaccination: Mathematical modeling analyses. *Vaccines* **8**(2020).
28. Usherwood, T., LaJoie, Z. & Srivastava, V. A model and predictions for COVID-19 considering population behavior and vaccination. *Scientific Reports* **11**, 12051 (2021).
29. Andersson, O., Campos-Mercade, P., Meier, A.N. & Wengström, E. Anticipation of COVID-19 Vaccines Reduces Social Distancing. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3765329. *SSRN* (2021).
30. Cassell, M.M., Halperin, D.T., Shelton, J.D. & Stanton, D. Risk compensation: the Achilles' heel of innovations in HIV prevention? *BMJ* **332**, 605-607 (2006).
31. Abu-Raddad, L.J., *et al.* Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough infections and reinfections. *medRxiv*, 2021.2007.2028.21261086 (2021).
32. Abu-Raddad, L.J., *et al.* Protection afforded by the BNT162b2 and mRNA-1273 COVID-19 vaccines in fully vaccinated cohorts with and without prior infection. *medRxiv*, 2021.2007.2025.21261093 (2021).
33. Khoury, D.S., *et al.* Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205-1211 (2021).
34. Seedat, S., *et al.* SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates. *medRxiv* 2020.11.29.20240416 (2020).

35. Jackson, M.L. & Nelson, J.C. The test-negative design for estimating influenza vaccine effectiveness. *Vaccine* **31**, 2165-2168 (2013).
36. Verani, J.R., *et al.* Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. *Vaccine* **35**, 3295-3302 (2017).
37. World Health Organization. COVID-19 clinical management: living guidance. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1>. Accessed on: May 15 2021. (2021).
38. World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as cause of death. Available from: https://www.who.int/classifications/icd/Guidelines_Cause_of_Death_COVID-19-20200420-EN.pdf?ua=1. Document Number: WHO/HQ/DDI/DNA/CAT. Accessed on May 31, 2021. (2021).
39. Ayoub, H.H., *et al.* Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. *J Glob Health* **11**, 05005 (2021).
40. Coyle, P.V., *et al.* SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. *iScience*, 102646 (2021).
41. Al-Thani, M.H., *et al.* SARS-CoV-2 infection is at herd immunity in the majority segment of the population of Qatar. *Open Forum Infectious Diseases* (2021).
42. Jeremijenko, A., *et al.* Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. *Emerg Infect Dis* **27**, 1343-1352 (2021).
43. Abu-Raddad, L.J., *et al.* COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar. *medRxiv*, 2021.2003.2006.21252601 (2021).
44. Vogels, C., Fauver, J. & Grubaugh, N. Multiplexed RT-qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 variants of concern V.3. [dx.doi.org/10.17504/protocols.io.br9vm966](https://doi.org/10.17504/protocols.io.br9vm966). (2021).
45. StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC. (2021).
46. Jacoby, P. & Kelly, H. Is it necessary to adjust for calendar time in a test negative design?: Responding to: Jackson ML, Nelson JC. The test negative design for estimating influenza vaccine effectiveness. *Vaccine* 2013;31(April (17)):2165-8. *Vaccine* **32**, 2942 (2014).
47. Pearce, N. Analysis of matched case-control studies. *BMJ* **352**, i969 (2016).
48. Rothman, K.J., Greenland, S. & Lash, T.L. *Modern epidemiology*, (Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, 2008).

Table 1. Demographic characteristics of cases (PCR-positive for SARS-CoV-2 Delta variant) and controls (PCR-negative) in samples used in the ≥ 14 -days-after-first-dose analysis of vaccine effectiveness of A) BNT162b2, B) mRNA-1273, and C) BNT162b2 or mRNA-1273.

Study type	A) Effectiveness of BNT162b2 vaccine		B) Effectiveness of mRNA-1273 vaccine		C) Effectiveness of BNT162b2 or mRNA-1273 vaccines	
Characteristics	Cases* (PCR-positive for Delta variant)	Controls* (PCR-negative)	Cases* (PCR-positive for Delta variant)	Controls* (PCR-negative)	Cases* (PCR-positive for Delta variant)	Controls* (PCR-negative)
Median age (IQR) — years	31 (24-37)	31 (24-37)	31 (24-37)	31 (24-37)	31 (24-37)	31 (25-38)
Age group — no. (%)						
<20 years	234 (14.4)	234 (14.4)	228 (13.9)	228 (13.9)	239 (13.8)	239 (13.8)
20-29 years	507 (31.3)	507 (31.3)	507 (30.9)	507 (30.9)	527 (30.4)	527 (30.4)
30-39 years	585 (36.1)	585 (36.1)	586 (35.7)	586 (35.7)	625 (36.1)	625 (36.1)
40-49 years	233 (14.4)	233 (14.4)	253 (15.4)	253 (15.4)	266 (15.4)	266 (15.4)
50-59 years	51 (3.2)	51 (3.2)	54 (3.3)	54 (3.3)	58 (3.4)	58 (3.4)
60-69 years	7 (0.4)	7 (0.4)	8 (0.5)	8 (0.5)	12 (0.7)	12 (0.7)
70+ years	4 (0.3)	4 (0.3)	4 (0.2)	4 (0.2)	4 (0.2)	4 (0.2)
Sex						
Male	1,314 (81.1)	1,314 (81.1)	1,336 (81.5)	1,336 (81.5)	1,392 (80.4)	1,392 (80.4)
Female	307 (18.9)	307 (18.9)	304 (18.5)	304 (18.5)	339 (19.6)	339 (19.6)
Nationality [†]						
Bangladeshi	146 (9.0)	146 (9.0)	158 (9.6)	158 (9.6)	166 (9.6)	166 (9.6)
Egyptian	10 (0.6)	10 (0.6)	10 (0.6)	10 (0.6)	13 (0.8)	13 (0.8)
Filipino	74 (4.6)	74 (4.6)	75 (4.6)	75 (4.6)	82 (4.7)	82 (4.7)
Indian	653 (40.3)	653 (40.3)	660 (40.2)	660 (40.2)	694 (40.1)	694 (40.1)
Nepalese	160 (9.9)	160 (9.9)	167 (10.2)	167 (10.2)	169 (9.8)	169 (9.8)
Pakistani	128 (7.9)	128 (7.9)	132 (8.1)	132 (8.1)	133 (7.7)	133 (7.7)
Qatari	226 (13.9)	226 (13.9)	215 (13.1)	215 (13.1)	233 (13.5)	233 (13.5)
Sri Lankan	15 (0.9)	15 (0.9)	20 (1.2)	20 (1.2)	22 (1.3)	22 (1.3)
Sudanese	13 (0.8)	13 (0.8)	12 (0.7)	12 (0.7)	14 (0.8)	14 (0.8)
Other nationalities [‡]	196 (12.1)	196 (12.1)	191 (11.7)	191 (11.7)	205 (11.8)	205 (11.8)
Reason for PCR testing						
Clinical suspicion	472 (29.1)	472 (29.1)	482 (29.4)	482 (29.4)	518 (29.9)	518 (29.9)
Contact tracing	146 (9.0)	146 (9.0)	148 (9.0)	148 (9.0)	157 (9.1)	157 (9.1)
Survey	179 (11.0)	179 (11.0)	178 (10.9)	178 (10.9)	193 (11.2)	193 (11.2)
Port of entry	441 (27.2)	441 (27.2)	452 (27.6)	452 (27.6)	471 (27.2)	471 (27.2)
Individual request	259 (16.0)	259 (16.0)	260 (15.9)	260 (15.9)	265 (15.3)	265 (15.3)
Healthcare routine testing	40 (2.5)	40 (2.5)	38 (2.3)	38 (2.3)	42 (2.4)	42 (2.4)
Pre-travel	84 (5.2)	84 (5.2)	82 (5.0)	82 (5.0)	85 (4.9)	85 (4.9)

*Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.

[†]Nationalities were chosen to represent the most populous groups in Qatar.

[‡]These comprise 35 other nationalities in Qatar in sample A, 35 other nationalities in sample B, and 36 other nationalities in sample C.

Table 2. Demographic characteristics of cases (PCR-positive for SARS-CoV-2 Delta variant) and controls (PCR-negative) in samples used in the ≥ 14 -days-after-second-dose analysis of vaccine effectiveness of A) BNT162b2, B) mRNA-1273, and C) BNT162b2 or mRNA-1273.

Study type	D) Effectiveness of BNT162b2 vaccine		E) Effectiveness of mRNA-1273 vaccine		F) Effectiveness of BNT162b2 or mRNA-1273 vaccines	
Characteristics	Cases* (PCR-positive for Delta variant)	Controls* (PCR-negative)	Cases* (PCR-positive for Delta variant)	Controls* (PCR-negative)	Cases* (PCR-positive for Delta variant)	Controls* (PCR-negative)
Median age (IQR) — years	31 (24-38)	31 (25-38)	31 (24-37)	31 (25-38)	32 (25-39)	32 (25-38)
Age group — no. (%)						
<20 years	248 (13.6)	248 (13.6)	231 (13.9)	231 (13.9)	256 (13.1)	256 (13.1)
20-29 years	551 (30.1)	551 (30.1)	514 (30.9)	514 (30.9)	580 (29.6)	580 (29.6)
30-39 years	641 (35.0)	641 (35.0)	596 (35.8)	596 (35.8)	688 (35.1)	688 (35.1)
40-49 years	274 (15.0)	274 (15.0)	259 (15.6)	259 (15.6)	312 (15.9)	312 (15.9)
50-59 years	82 (4.5)	82 (4.5)	55 (3.3)	55 (3.3)	88 (4.5)	88 (4.5)
60-69 years	25 (1.4)	25 (1.4)	7 (0.4)	7 (0.4)	26 (1.3)	26 (1.3)
70+ years	9 (0.5)	9 (0.5)	4 (0.2)	4 (0.2)	9 (0.5)	9 (0.5)
Sex						
Male	1,443 (78.9)	1,443 (78.9)	1,342 (80.6)	1,342 (80.6)	1,530 (78.1)	1,530 (78.1)
Female	387 (21.2)	387 (21.2)	324 (19.5)	324 (19.5)	429 (21.9)	429 (21.9)
Nationality [†]						
Bangladeshi	149 (8.1)	149 (8.1)	161 (9.7)	161 (9.7)	171 (8.7)	171 (8.7)
Egyptian	14 (0.8)	14 (0.8)	11 (0.7)	11 (0.7)	18 (0.9)	18 (0.9)
Filipino	80 (4.4)	80 (4.4)	77 (4.6)	77 (4.6)	89 (4.5)	89 (4.5)
Indian	673 (36.8)	673 (36.8)	663 (39.8)	663 (39.8)	721 (36.8)	721 (36.8)
Nepalese	165 (9.0)	165 (9.0)	168 (10.1)	168 (10.1)	175 (8.9)	175 (8.9)
Pakistani	137 (7.5)	137 (7.5)	132 (7.9)	132 (7.9)	142 (7.3)	142 (7.3)
Qatari	346 (18.9)	346 (18.9)	223 (13.4)	223 (13.4)	355 (18.1)	355 (18.1)
Sri Lankan	19 (1.0)	19 (1.0)	21 (1.3)	21 (1.3)	26 (1.3)	26 (1.3)
Sudanese	17 (0.9)	17 (0.9)	13 (0.8)	13 (0.8)	20 (1.0)	20 (1.0)
Other nationalities [‡]	230 (12.6)	230 (12.6)	197 (11.8)	197 (11.8)	242 (12.4)	242 (12.4)
Reason for PCR testing						
Clinical suspicion	571 (31.2)	571 (31.2)	495 (29.7)	495 (29.7)	625 (31.9)	625 (31.9)
Contact tracing	159 (8.7)	159 (8.7)	148 (8.9)	148 (8.9)	169 (8.6)	169 (8.6)
Survey	200 (10.9)	200 (10.9)	179 (10.7)	179 (10.7)	216 (11.0)	216 (11.0)
Port of entry	469 (25.6)	469 (25.6)	454 (27.3)	454 (27.3)	502 (25.6)	502 (25.6)
Individual request	276 (15.1)	276 (15.1)	265 (15.9)	265 (15.9)	287 (14.7)	287 (14.7)
Healthcare routine testing	45 (2.5)	45 (2.5)	39 (2.3)	39 (2.3)	48 (2.5)	48 (2.5)
Pre-travel	110 (6.0)	110 (6.0)	86 (5.2)	86 (5.2)	112 (5.7)	112 (5.7)

*Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.

[†]Nationalities were chosen to represent the most populous groups in Qatar.

[‡]These comprise 41 other nationalities in Qatar in sample A, 36 other nationalities in sample B, and 40 other nationalities in sample C.

Table 3. Effectiveness of the BNT162b2 and mRNA-1273 vaccines against the Delta variant ≥ 14 days after the first dose and ≥ 14 days after the second dose.

	≥14 days after first dose and no second dose					≥14 days after second dose				
	Cases* (PCR-positive)		Controls* (PCR-negative)		Effectiveness in % (95% CI) [†]	Cases* (PCR-positive)		Controls* (PCR-negative)		Effectiveness in % (95% CI) [†]
	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated		Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	
Effectiveness against infection										
BNT162b2	19	1,602	52	1,569	64.2 (38.1-80.1)	209	1,621	397	1,433	53.5 (43.9-61.4)
mRNA-1273	11	1,629	51	1,589	79.0 (58.9-90.1)	22	1,644	135	1,531	84.8 (75.9-90.8)
BNT162b2 or mRNA-1273	31	1,700	96	1,635	68.9 (52.7-80.1)	231	1,728	466	1,493	57.2 (48.9-64.1)
Effectiveness against severity, criticality, and fatality[‡]										
BNT162b2	0	49	4	45	100.0 [§] (8.2-100.0)	3	54	20	37	89.7 [‡] (61.0-98.1)
mRNA-1273	0	50	5	45	100.0 [§] (28.1-100.0)	0	53	6	47	100.0 [§] (41.2-100.0)
BNT162b2 or mRNA-1273	0	50	1	49	100.0 [§] (0.0-100.0)	3	57	25	35	92.6 [‡] (72.7-98.6)

*Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.

[†]Vaccine effectiveness was estimated using the test-negative, case-control study design^{35,36}.

[‡]Effectiveness against severe, critical, or fatal COVID-19 disease. Severity³⁷, criticality³⁷, and fatality³⁸ were defined as per World Health Organization guidelines.

[§]Exact confidence levels were not possible with zero count cells. Confidence intervals were calculated using the Cornfield method.

Table 4. Sensitivity analyses for effectiveness of the BNT162b2 and mRNA-1273 vaccines against the Delta variant ≥ 14 days after the first dose and ≥ 14 days after the second dose, adjusting for sex, age, nationality, reason for PCR testing, and calendar week in logistic regression analysis.

	≥14 days after first dose and no second dose					≥14 days after second dose				
	Cases* (PCR-positive)		Controls* (PCR-negative)		Effectiveness in % (95% CI)†	Cases* (PCR-positive)		Controls* (PCR-negative)		Effectiveness in % (95% CI)†
	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated		Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	
Effectiveness against infection										
BNT162b2	19	1,602	52	1,569	65.5 (40.9-79.9)	209	1,621	397	1,433	59.6 (50.7-66.9)
mRNA-1273	11	1,629	51	1,589	79.7 (60.8-89.5)	22	1,644	135	1,531	86.1 (78.0-91.3)
BNT162b2 or mRNA-1273	31	1,700	96	1,635	70.5 (55.2-80.6)	231	1,728	466	1,493	63.3 (55.7-69.6)
Effectiveness against severity, criticality, and fatality‡										
BNT162b2	0	49	4	45	100.0§ (Omitted)	3	54	20	37	97.3‡ (84.4-99.5)
mRNA-1273	0	50	5	45	100.0§ (Omitted)	0	53	6	47	100.0§ (Omitted)
BNT162b2 or mRNA-1273	0	50	1	49	100.0§ (Omitted)	3	57	25	35	98.8‡ (91.7-99.8)

*Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.

[†]Vaccine effectiveness was estimated using the test-negative, case-control study design^{35,36}. Age was included as a dichotomous variable: <50 versus ≥ 50 . Nationality was categorized into 3 groups: Bangladeshis, Indians, Nepalese, Pakistanis, and Sri Lankans (Group 1); Qataris (Group 2); and all other nationalities (Group 3), as informed by the observed epidemiology and exposure risk assessments of SARS-CoV-2 infection in Qatar^{10,39-43}.

[‡]Effectiveness against severe, critical, or fatal COVID-19 disease. Severity³⁷, criticality³⁷, and fatality³⁸ were defined as per World Health Organization guidelines.

[§]Confidence intervals could not be generated in logistic regression as there were no events among those vaccinated.

Table 5. Effectiveness of the BNT162b2 and mRNA-1273 vaccines against symptomatic and asymptomatic infection with the Delta variant ≥ 14 days after the first dose and ≥ 14 days after the second dose.

	≥14 days after first dose and no second dose					≥14 days after second dose				
	Cases* (PCR-positive)		Controls* (PCR-negative)		Effectiveness in % (95% CI) [†]	Cases* (PCR-positive)		Controls* (PCR-negative)		Effectiveness in % (95% CI) [†]
	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated		Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	
Effectiveness against symptomatic infection[‡]										
BNT162b2	8	464	32	440	76.3 (46.7-90.7)	98	473	183	388	56.1 (41.4-67.2)
mRNA-1273	5	477	33	449	85.7 (62.7-95.7)	9	486	57	438	85.8 (70.6-93.9)
BNT162b2 or mRNA-1273	13	505	61	457	80.7 (63.9-90.4)	107	518	220	405	62.0 (50.0-71.1)
Effectiveness against asymptomatic infection[§]										
BNT162b2	6	681	8	679	25.2 (0.0-78.7)	73	684	108	649	35.9 (11.1-53.9)
mRNA-1273	3	696	7	692	57.4 (0.0-92.9)	7	697	34	670	80.2 (54.2-92.6)
BNT162b2 or mRNA-1273	9	723	16	716	44.3 (0.0-78.4)	80	726	125	681	40.0 (18.2-56.1)

*Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.

[†]Vaccine effectiveness was estimated using the test-negative, case-control study design^{35,36}.

[‡]A symptomatic infection is defined as a PCR-positive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.

[§]An asymptomatic infection is defined as a PCR-positive test conducted with no reported presence of symptoms compatible with a respiratory tract infection. That is, the PCR testing was done as part of a survey, for pre-travel requirement, or at the port of entry into the country.

Methods

Data sources, study population, and study design

This study was conducted in the resident population of Qatar. Coronavirus Disease 2019 (COVID-19) laboratory testing, vaccination, clinical infection data, and related demographic details were extracted from the integrated nationwide digital-health information platform that hosts the national, federated SARS-CoV-2 databases. These databases are complete and have captured all SARS-CoV-2-related data since epidemic onset. Nearly all individuals were vaccinated (free of charge) in Qatar and not elsewhere. In rare situations in which an individual received COVID-19 vaccination outside Qatar, the individual's vaccination details were still recorded in the health system at the port of entry (airport) upon return to Qatar, in order to fulfill national requirements and to benefit from privileges associated with vaccination, such as quarantine exemption.

Vaccine effectiveness was estimated using the test-negative, case-control study design, a standard design for assessing vaccine effectiveness against influenza^{35,36}. Key to this design is the control of bias arising from misclassification of infection and differences in health care-seeking behavior between vaccinated and unvaccinated individuals^{35,36}. Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for SARS-CoV-2 polymerase chain reaction (PCR) testing, and calendar week of PCR test. Matching of cases and controls was performed to control for known differences in the risk of exposure to infection in Qatar^{10,40-42}.

Effectiveness was estimated against documented infection (defined as a PCR-positive swab regardless of the reason for PCR testing or presence of symptoms) with the Delta (B.1.617.2) variant, as well as against severe, critical, or fatal COVID-19 disease due to Delta infection. Classification of COVID-19 case severity (acute-care hospitalizations)¹², criticality (ICU

hospitalizations)¹², and fatality¹³ followed the World Health Organization guidelines, and assessments were made by trained medical personnel using individual chart reviews (see below).

All records of PCR testing for those vaccinated and unvaccinated during the study duration were examined. All persons who received mixed vaccines, or who received a vaccine other than BNT162b2 or mRNA-1273 were excluded. Every case that met the inclusion criteria (a Delta case) and that could be matched to a control was included in the analysis. Both PCR-test outcomes and vaccination status were ascertained at the time of the PCR test. Each person that had a positive PCR test result and hospital admission was subject to an infection severity assessment every three days until discharge or death. Individuals who progressed to COVID-19 disease between the time of the positive PCR test result and the end of the study were classified based on their worst outcome, starting with death¹³, followed by critical disease¹², and then severe disease¹² (see below).

The study was approved by the Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards with waiver of informed consent. The STROBE checklist can be found in Supplementary Table 1.

COVID-19 severity, criticality, and fatality classification

Severe COVID-19 disease was defined per WHO classification as a SARS-CoV-2 infected person with “oxygen saturation of <90% on room air, and/or respiratory rate of >30 breaths/minute in adults and children >5 years old (or ≥60 breaths/minute in children <2 months old or ≥50 breaths/minute in children 2–11 months old or ≥40 breaths/minute in children 1–5 years old), and/or signs of severe respiratory distress (accessory muscle use and inability to complete full sentences, and, in children, very severe chest wall indrawing, grunting, central

cyanosis, or presence of any other general danger signs)”³⁷. Detailed WHO criteria for classifying SARS-CoV-2 infection severity can be found in the WHO technical report³⁷.

Critical COVID-19 disease was defined per WHO classification as a SARS-CoV-2 infected person with “acute respiratory distress syndrome, sepsis, septic shock, or other conditions that would normally require the provision of life sustaining therapies such as mechanical ventilation (invasive or non-invasive) or vasopressor therapy”³⁷. Detailed WHO criteria for classifying SARS-CoV-2 infection criticality can be found in the WHO technical report³⁷.

COVID-19 death was defined per WHO classification as “a death resulting from a clinically compatible illness, in a probable or confirmed COVID-19 case, unless there is a clear alternative cause of death that cannot be related to COVID-19 disease (e.g. trauma). There should be no period of complete recovery from COVID-19 between illness and death. A death due to COVID-19 may not be attributed to another disease (e.g. cancer) and should be counted independently of preexisting conditions that are suspected of triggering a severe course of COVID-19”. Detailed WHO criteria for classifying COVID-19 death can be found in the WHO technical report³⁸.

Classification of infections by variant type

Surveillance for SARS-CoV-2 variants in Qatar is based on viral genome sequencing and multiplex, real-time reverse-transcription PCR (RT-qPCR) variant screening⁴⁴ of random positive clinical samples²⁻⁶, and complemented by deep sequencing of wastewater samples². The ascertainment of the B.1.617.2 (Delta) cases in this study was based on the results of the weekly RT-qPCR genotyping of the positive clinical samples^{2,4}. Between March 23, 2021 and July 21, 2021, RT-qPCR genotyping identified 5,394 (50.6%) B.1.351-like cases, 3,046 (28.6%) B.1.1.7-like cases, 2,175 (20.4%) “other” variant cases, and 41 (0.4%) B.1.375-like and B.1.258-like cases in 10,656 randomly collected SARS-CoV-2-positive specimens^{2,4}.

The accuracy of the RT-qPCR genotyping was verified against either Sanger sequencing of the receptor-binding domain (RBD) of SARS-CoV-2 surface glycoprotein (S) gene, or by viral whole-genome sequencing on a Nanopore GridION sequencing device. From 236 random samples (27 B.1.1.7-like, 186 B.1.351/P.1-like, and 23 “other” variants), the PCR genotyping results for B.1.1.7-like, B.1.351/P.1-like, and ‘other’ variants were in 88.8% (23 out of 27), 99.5% (185 out of 186), and 100% (23 out of 23) agreement with the SARS-CoV-2 lineages assigned by sequencing.

Within the “other” variant category, Sanger sequencing and/or Illumina sequencing of the RBD of SARS-CoV-2 spike gene on 450 random samples confirmed that 433 (96.2%) were B.1.617.2 cases, 8 (1.8%) were B.1.617.1 cases, 3 (0.7%) were B.1 cases, 1 (0.2%) was a P.1 case, and 1 (0.2%) was a B.1.617.3 case, with 5 (1.1%) samples failing sequencing^{2,4}. Accordingly, a Delta case was proxied as any “other” case identified through the RT-qPCR based variant screening.

Laboratory methods

Nasopharyngeal and/or oropharyngeal swabs (Huachenyang Technology, China) were collected for PCR testing and placed in Universal Transport Medium (UTM). Aliquots of UTM were: extracted on a QIAasympy platform (QIAGEN, USA) and tested with real-time reverse-transcription PCR (RT-qPCR) using TaqPath™ COVID-19 Combo Kits (Thermo Fisher Scientific, USA) on an ABI 7500 FAST (ThermoFisher, USA); tested directly on the Cepheid GeneXpert system using the Xpert Xpress SARS-CoV-2 (Cepheid, USA); or loaded directly into a Roche cobas® 6800 system and assayed with a cobas® SARS-CoV-2 Test (Roche, Switzerland). The first assay targets the viral S, N, and ORF1ab gene regions. The second targets the viral N and E-gene regions, and the third targets the ORF1ab and E-gene regions.

All tests were conducted at the HMC Central Laboratory or Sidra Medicine Laboratory, following standardized protocols.

Statistical analysis

Descriptive statistics (frequency distributions and measures of central tendency) were used to characterize the study samples. The odds ratio, comparing odds of vaccination among cases to that among controls, and its associated 95% confidence interval (CI) were calculated using the exact method. Confidence intervals were not adjusted for multiplicity. Interactions were not investigated. Vaccine effectiveness at different time frames and its associated 95% CI were then calculated by applying the following equation^{35,36}:

$$\text{Vaccine effectiveness} = 1 - \frac{\text{vaccinated among cases} \times \text{unvaccinated among controls}}{\text{vaccinated among controls} \times \text{unvaccinated among cases}}$$

Statistical analyses were conducted in STATA/SE version 17.0⁴⁵.

Additional analyses

To ensure that vaccine effectiveness estimates were not biased by epidemic phase^{35,46}, the gradual roll-out of vaccination during the study^{35,46}, and other confounders^{47,48}, a sensitivity analysis was conducted by adjusting for the matching factors in logistic regression, that is sex, age, nationality, reason for PCR testing, and calendar week of PCR test (Table 4).

Additional analyses were conducted to estimate vaccine effectiveness against symptomatic infection, defined as a PCR-positive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection, and against asymptomatic infection, defined as a PCR-positive test conducted with no reported presence of symptoms compatible

with a respiratory tract infection, that is the PCR testing was done as part of a survey, for pre-travel requirement, or at port of entry into the country.

Data availability

The dataset of this study is a property of the Qatar Ministry of Public Health that was provided to the researchers through a restricted-access agreement that prevents sharing the dataset with a third party or publicly. Future access to this dataset can be considered through a direct application for data access to Her Excellency the Minister of Public Health (<https://www.moph.gov.qa/english/Pages/default.aspx>). Aggregate data are available within the manuscript and its Supplementary information.

Supplementary Material

Table of Contents

Supplementary Data 1. Flowchart describing the population selection process for investigating BNT162b2 vaccine effectiveness against infection with the SARS-CoV-2 Delta variant.	2
Supplementary Data 2. Flowchart describing the population selection process for investigating mRNA-1273 vaccine effectiveness against infection with the SARS-CoV-2 Delta variant.	3
Supplementary Data 3. Flowchart describing the population selection process for investigating the BNT162b2 and mRNA-1273 vaccines effectiveness against infection with the SARS-CoV-2 Delta variant.	4
Supplementary Table 1. STROBE checklist of items for case-control studies	5

Supplementary Data 1. Flowchart describing the population selection process for investigating BNT162b2 vaccine effectiveness against infection with the SARS-CoV-2 Delta variant.

Supplementary Data 2. Flowchart describing the population selection process for investigating mRNA-1273 vaccine effectiveness against infection with the SARS-CoV-2 Delta variant.

Supplementary Data 3. Flowchart describing the population selection process for investigating the BNT162b2 and mRNA-1273 vaccines effectiveness against infection with the SARS-CoV-2 Delta variant.

Supplementary Table 1. STROBE checklist for case-control studies

	Item No	Recommendation	Main text page
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design	20-21
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	20-23, & Supplementary Data 1-3
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	20-23, Supplementary Data 1-3
		(b) For matched studies, give matching criteria and the number of controls per case	20-21 & Supplementary Data 1-3
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	20-24
Data sources/measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	20-24
Bias	9	Describe any efforts to address potential sources of bias	24-25
Study size	10	Explain how the study size was arrived at	20-21 & Supplementary Data 1-3
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	21-24
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	24-25
		(b) Describe any methods used to examine subgroups and interactions	24-25
		(c) Explain how missing data were addressed	NA, see p. 20
		(d) If applicable, explain how matching of cases and controls was addressed	20
		(e) Describe any sensitivity analyses	24-25
Results			
Participants	13	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Supplementary Data 1-3
		(b) Give reasons for non-participation at each stage	Supplementary Data 1-3
		(c) Consider use of a flow diagram	Supplementary Data 1-3
Descriptive data	14	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	3-4 & Tables 1-2
		(b) Indicate number of participants with missing data for each variable of interest	NA, see p. 20
Outcome data	15	Report numbers in each exposure category, or summary measures of exposure	4-6, Tables 3-5
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	5-6, Tables 3-5
		(b) Report category boundaries when continuous variables were categorized	Tables 3-5
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	6-7, Tables 4-5
Discussion			
Key results	18	Summarise key results with reference to study objectives	7-9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9-10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10
Generalisability	21	Discuss the generalisability (external validity) of the study results	9-10
Other information			

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	11
---------	----	---	----

Abbreviations: NA, not applicable; Supp, Supplementary.